ALK(SZ:002940) Jin Rong Jie·2025-07-31 03:41Core Viewpoint - The stock of Anglikon Pharmaceutical Co., Ltd. experienced a significant increase, reaching a 10.0% limit up, indicating strong market interest and confidence in the company's performance and prospects [1]. Company Overview - Anglikon Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, and operates as a modern pharmaceutical enterprise that integrates the research, production, and development of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and formulations [1]. - The company specializes in various therapeutic areas, including anti-infection, cardiovascular, and anesthesia pain relief, and has established a complete pharmaceutical industry chain [1]. - Anglikon is recognized as the largest global producer of α-keto acid APIs and has multiple production bases along with over ten subsidiaries, positioning itself among the top 200 pharmaceutical companies in China [1]. Financial Performance - As of March 31, the number of shareholders for Anglikon was 12,300, with an average of 15,100 circulating shares per shareholder [2]. - For the first quarter of 2025, Anglikon reported a revenue of 346 million yuan, reflecting a year-on-year decrease of 15.31% [2]. - The net profit attributable to shareholders for the same period was approximately 15.91 million yuan, which represents a year-on-year decline of 43.63% [2].